Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

The advent of immune checkpoint inhibitors (ICIs) has dramatically changed the treatment of patients with locally advanced to resectable and metastatic non-small cell lung cancer (NSCLC). Now, ICIs are undergoing evaluation as neoadjuvant therapy in patients with early-stage, resectable NSCLC using candidate surrogate endpoints of clinical efficacy, i.e., major pathologic response (MPR, <= 10% viable tumor cells in resected tumors). The initial results from early, small-scale trials are encouraging; however, they also reveal that a substantial number of patients with operable disease may not benefit from neoadjuvant ICIs. Consequently, much investigative effort is currently directed toward identifying mechanisms of resistance to ICI therapy in resectable NSCLC. There is also an urgent need for biomarkers that could be used to guide the clinical decision-making process and maximize the clinical benefit of ICIs in patients with early-stage, resectable NSCLC. lIere, we summarize the initial results from the trials of neoadjuvant ICIs in patients with early-stage and locally advanced operable NSCLC and review the findings of studies investigating emerging biomarkers associated with those trials.

Automated summary

The advent of immune checkpoint inhibitors has significantly changed the treatment of patients with locally advanced to resectable and metastatic non-small cell lung cancer. While early results of neoadjuvant ICIs in early-stage NSCLC are promising, further research is needed to explore efficacy, resistance mechanisms, and biomarkers for predicting clinical benefit.